Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Pulmonx Corporation develops and commercializes minimally invasive devices for treating severe emphysema/COPD, primarily the Zephyr Endobronchial Valve system. The company operates in a niche medical device market with FDA approval and Medicare reimbursement, targeting approximately 300,000 eligible patients in the US with severe emphysema who have failed medical management. Despite strong gross margins (74%), the company remains deeply unprofitable with negative 69% operating margins as it invests in commercial expansion and physician training.
Pulmonx generates revenue by selling single-use Zephyr Valve kits (typically 4-6 valves per procedure at estimated $15,000-20,000 per kit) to hospitals performing bronchoscopic lung volume reduction procedures. The business model relies on converting pulmonologists to adopt the procedure through clinical training programs, building hospital accounts with capital equipment (Chartis system for patient assessment), and securing favorable reimbursement. Medicare covers the procedure (CPT code established), providing approximately $30,000-35,000 per case reimbursement to hospitals. Pricing power exists due to lack of direct competition in endobronchial valve therapy, though alternative surgical approaches (lung volume reduction surgery, transplant) provide indirect competition. The company's competitive advantage stems from clinical trial data (LIBERATE, EMPROVE studies), first-mover status with FDA approval, and established physician relationships.
Quarterly procedure volume growth and US commercial adoption rates - number of trained physicians and active hospital accounts
Medicare reimbursement policy changes or coverage expansions to broader COPD patient populations
Clinical trial results for label expansion (heterogeneous emphysema, less severe disease stages)
Competitive threats from Boston Scientific, Olympus, or other medical device companies entering bronchoscopic lung volume reduction
Cash burn rate and runway to profitability - company has limited cash reserves relative to operating losses
Medicare reimbursement cuts or policy changes restricting coverage criteria could eliminate the economic model for hospitals performing procedures
Technological obsolescence if less invasive pharmacological treatments or alternative bronchoscopic approaches emerge for emphysema management
Limited addressable market (300,000 eligible patients in US) caps long-term revenue potential at $1.5-2.0B assuming 50% penetration
Regulatory risk if FDA requires additional clinical trials for label maintenance or expansion, delaying growth initiatives
Boston Scientific or other large medical device companies could develop competing endobronchial valve systems with superior clinical data or pricing
Lung volume reduction surgery (LVRS) remains gold standard with stronger clinical outcomes for appropriate candidates, limiting valve adoption
International competitors (Olympus Spiration Valve System in Europe) could enter US market with differentiated technology
Negative $67M annual operating cash flow with limited cash reserves creates going concern risk if revenue growth stalls - likely needs capital raise within 12-18 months
Debt/equity of 0.94x indicates some leverage, though absolute debt levels appear manageable given current ratio of 4.86x
Equity dilution risk from future financing rounds given stock price decline of 78% over past year reduces attractiveness of equity raises
low - Elective medical procedures for severe emphysema patients are clinically driven rather than discretionary. However, hospital capital budgets for new technology adoption can be affected during recessions, potentially slowing new account additions. Patient out-of-pocket costs are minimal with Medicare coverage, reducing direct consumer spending sensitivity. The 300,000+ eligible patient population with severe disease creates consistent underlying demand regardless of economic conditions.
Rising interest rates negatively impact valuation multiples for unprofitable growth companies, as future cash flows are discounted more heavily. The company's cash balance (estimated $40-60M based on current ratio of 4.86x) earns higher returns in rising rate environments, partially offsetting operating losses. Financing costs are minimal given low debt levels (0.94x debt/equity), but future capital raises become more expensive in high-rate environments. Hospital capital equipment purchasing decisions may be delayed if healthcare systems face higher borrowing costs.
Minimal direct credit exposure. Revenue is primarily from hospital systems with strong credit profiles and Medicare reimbursement backing. Accounts receivable risk is low given the healthcare institutional customer base. The company's own credit access matters more - ability to raise capital if needed depends on equity market conditions and investor appetite for unprofitable medtech companies.
growth - Investors are betting on commercial adoption curve acceleration and path to profitability within 3-5 years. The 22% revenue growth rate and large addressable market attract growth-oriented healthcare specialists. However, the 78% one-year decline and deep losses have eliminated momentum investors. Current $100M market cap suggests only specialized small-cap healthcare funds and insiders remain. High-risk/high-reward profile given binary outcomes around Medicare policy, competitive entry, and cash runway.
high - Stock exhibits extreme volatility typical of small-cap unprofitable medical device companies. The 78% one-year decline demonstrates downside risk, while limited liquidity (small market cap) amplifies price swings on news. Beta likely exceeds 1.5x relative to healthcare sector. Quarterly earnings reports, clinical trial data, and reimbursement policy announcements drive 20-40% single-day moves.
